JP2016169229A5 - - Google Patents

Download PDF

Info

Publication number
JP2016169229A5
JP2016169229A5 JP2016120503A JP2016120503A JP2016169229A5 JP 2016169229 A5 JP2016169229 A5 JP 2016169229A5 JP 2016120503 A JP2016120503 A JP 2016120503A JP 2016120503 A JP2016120503 A JP 2016120503A JP 2016169229 A5 JP2016169229 A5 JP 2016169229A5
Authority
JP
Japan
Prior art keywords
pik3ca
subject
mutation
neratinib
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016120503A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016169229A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016169229A publication Critical patent/JP2016169229A/ja
Publication of JP2016169229A5 publication Critical patent/JP2016169229A5/ja
Withdrawn legal-status Critical Current

Links

JP2016120503A 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー Withdrawn JP2016169229A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28582109P 2009-12-11 2009-12-11
US61/285,821 2009-12-11
US28787209P 2009-12-18 2009-12-18
US61/287,872 2009-12-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015051863A Division JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017038956A Division JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Publications (2)

Publication Number Publication Date
JP2016169229A JP2016169229A (ja) 2016-09-23
JP2016169229A5 true JP2016169229A5 (cg-RX-API-DMAC7.html) 2017-04-06

Family

ID=43628745

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010273484A Withdrawn JP2011121944A (ja) 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2016120503A Withdrawn JP2016169229A (ja) 2009-12-11 2016-06-17 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010273484A Withdrawn JP2011121944A (ja) 2009-12-11 2010-12-08 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2015051863A Pending JP2015110669A (ja) 2009-12-11 2015-03-16 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017038956A Withdrawn JP2017101072A (ja) 2009-12-11 2017-03-02 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2018246698A Withdrawn JP2019052187A (ja) 2009-12-11 2018-12-28 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2020119091A Withdrawn JP2020169212A (ja) 2009-12-11 2020-07-10 ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
JP2021192872A Pending JP2022022296A (ja) 2009-12-11 2021-11-29 ホスファチジルイノシトール－３－キナーゼ経路バイオマーカー

Country Status (5)

Country Link
US (4) US20130189274A1 (cg-RX-API-DMAC7.html)
EP (2) EP3575413A1 (cg-RX-API-DMAC7.html)
JP (7) JP2011121944A (cg-RX-API-DMAC7.html)
CA (1) CA2783743C (cg-RX-API-DMAC7.html)
WO (1) WO2011070499A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN107308130B (zh) 2009-11-09 2021-06-15 惠氏有限责任公司 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
US20140298493A1 (en) * 2011-07-28 2014-10-02 Somasekar Seshagiri PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
HK1202265A1 (en) * 2012-06-08 2015-09-25 霍夫曼-拉罗奇有限公司 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
CN105274188A (zh) * 2014-05-29 2016-01-27 北京雅康博生物科技有限公司 Pik3ca基因突变检测试剂盒
WO2016187157A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
US9607375B2 (en) * 2015-06-03 2017-03-28 Eileen B. Gallagher Biological data annotation and visualization
US10672505B2 (en) 2015-06-03 2020-06-02 General Electric Company Biological data annotation and visualization
US9953133B2 (en) 2015-06-03 2018-04-24 General Electric Company Biological data annotation and visualization
KR20190054826A (ko) * 2017-11-14 2019-05-22 한미약품 주식회사 암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
IT201800010730A1 (it) * 2018-11-30 2020-05-30 Univ Degli Studi Milano Metodo per classificare pazienti affetti da tumore alla mammella idonei per immunoterapia
MA54907A (fr) 2019-02-06 2022-05-11 Venthera Inc Inhibiteurs de phosphoinositide 3-kinase topiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399865B2 (en) 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
EP1856292B1 (en) * 2005-03-09 2013-10-30 Abbott Laboratories Diagnostic methods for identifying candidate patients for the treatment with trastuzumab.
EP1899463A4 (en) * 2005-05-09 2009-11-25 Ariad Pharma Inc BIOMARKERS FOR EVALUATING THE PROBABILITY THAT A TUMOR IS SENSITIVE TO A MTOR INHIBITOR
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
AU2008239594B2 (en) * 2007-04-13 2013-10-24 Beth Israel Deaconess Medical Center Methods for treating cancer resistant to ErbB therapeutics
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof

Similar Documents

Publication Publication Date Title
JP2016169229A5 (cg-RX-API-DMAC7.html)
Molinari et al. Heterogeneity in colorectal cancer: a challenge for personalized medicine?
US20230146253A1 (en) Methods related to bronchial premalignant lesion severity and progression
Sukawa et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer
Ting et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma
Nomura et al. Distinct molecular profile of diffuse cerebellar gliomas
EP2944961A1 (en) Markers for cancer prognosis and therapy and methods of use
Sung et al. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy
Li et al. Current status of ctDNA in precision oncology for hepatocellular carcinoma
CN105705658A (zh) 随时间检测疾病中的突变
Hufnagl et al. A modified Phenol-chloroform extraction method for isolating circulating cell free DNA of tumor patients
Haghbin et al. The role of CXCR3 and its ligands CXCL10 and CXCL11 in the pathogenesis of celiac disease
JP2013178260A5 (cg-RX-API-DMAC7.html)
JP2014503180A5 (cg-RX-API-DMAC7.html)
CN110452986A (zh) 一种检测结直肠癌相关基因变异的引物及其应用
CN113056267A (zh) Plk1靶磷酸化状态以及用plk1抑制剂治疗癌症
Stewart et al. New therapies for clear cell ovarian carcinoma
WO2020092998A1 (en) Identification of pde3 modulator responsive cancers
WO2012076582A1 (en) Agtr1 as a marker for bevacizumab combination therapies
Yao et al. Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment
Zavarykina et al. Circulating tumor DNA is a variant of liquid biopsy with predictive and prognostic clinical value in breast cancer patients
Agirre-Lizaso et al. Targeting the heterogeneous tumour-associated macrophages in hepatocellular carcinoma
US20230332246A1 (en) Methods for characterizing biological samples
Berardi et al. Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy
Sun et al. Impact of pentraxin 3 genetic variants on uterine cervical cancer clinicopathologic characteristics